More on Wet Macular Degeneration: Eylea

Dr. Mark Michels

By Christine Davis:

Dr. Mark Michels and his team at Retina Care Specialists provided North County Current with an update on a medication, Eylea (VegF Trap Eye), for the treatment of Wet Macular Degeneration that the FDA approved on November 18.

See our earlier story here.

And our follow-up story here.

So, here’s a quick recap: Lucentis had been FDA approved for Wet Macular Degeneration. A second (much less expensive) drug, Avastin,  has also been found to be just as good as Lucentis, according to the report from the Comparison of AMD Treatments Trials (CATT), which was published online in the New England Journal of Medicine on Sunday, May 1, 2011.
Now, Eylea (Vegf Trap Eye) has been approved by the FDA for treatment of Wet Macular Degeneration.

Eylea can be injected into the eye less frequently than the current standard, Genentech’s Lucentis, according to the labels of the two drugs. Eylea is also slightly less expensive, at $1,850 an injection versus $1,950 for Lucentis. Expectations are that Eylea will save the health care system approximately $8,000 a year per patient, factoring in the fewer injections and also fewer doctor visits and loss of time off from work compared to Lucentis.

“We think that Eylea will be a great addition to our armamentarium against wet ARMD. Now we have a second FDA approved weapon against the leading cause of blindness in the Western world. By treating half as frequently in the long run, the new drug will help reduce the burden of time and expense both for patients and those who bring them to the office. And, since the drug is priced less than the cost of Lucentis, the costs to society overall will be reduced as well,” said Mark Michels, MD, FACS. “We look forward to having Eylea available for our patients in the next couple of weeks.”

Retina Care Specialists, with offices in Palm Beach Gardens, Stuart, and Port St. Lucie, was chosen to participate in the Vegf Trap Eye study in this region over the past three years and its doctors were instrumental in providing valuable research data to Regeneron upon its submission to the FDA for review and ultimate approval.



Did you like this? Share it:
Christine Davis

About Christine Davis

Christine Davis is a freelance writer who covers real estate, homes, health and science.